FY2017 Earnings Forecast for Johnson & Johnson (JNJ) Issued By Jefferies Group

Johnson & Johnson (NYSE:JNJ) – Jefferies Group raised their FY2017 earnings per share (EPS) estimates for shares of Johnson & Johnson in a research note issued on Wednesday. Jefferies Group analyst J. Holford now anticipates that the company will post earnings of $7.22 per share for the year, up from their previous estimate of $7.11. Jefferies Group has a “Buy” rating and a $157.00 price objective on the stock.

Several other research analysts have also recently commented on JNJ. Vetr cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $129.62 target price for the company. in a report on Friday. Cowen and Company set a $147.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Friday, October 6th. Piper Jaffray Companies reiterated a “hold” rating and issued a $120.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 4th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Wednesday, October 4th. Finally, J P Morgan Chase & Co raised their target price on shares of Johnson & Johnson from $140.00 to $148.00 and gave the stock an “overweight” rating in a report on Wednesday, August 16th. Five analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $135.98.

WARNING: “FY2017 Earnings Forecast for Johnson & Johnson (JNJ) Issued By Jefferies Group” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://sportsperspectives.com/2017/10/13/fy2017-earnings-forecast-for-johnson-johnson-jnj-issued-by-jefferies-group.html.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.04. The business had revenue of $18.84 billion during the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The company’s revenue was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.74 earnings per share.

In related news, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the transaction, the vice president now owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the transaction, the vice president now directly owns 230,342 shares in the company, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in Johnson & Johnson by 1.5% during the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after acquiring an additional 3,023,110 shares in the last quarter. BlackRock Inc. raised its position in Johnson & Johnson by 2.6% during the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after acquiring an additional 4,332,612 shares in the last quarter. State Street Corp raised its position in Johnson & Johnson by 4.3% during the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after acquiring an additional 6,656,371 shares in the last quarter. FMR LLC raised its position in Johnson & Johnson by 5.9% during the second quarter. FMR LLC now owns 27,237,648 shares of the company’s stock valued at $3,603,268,000 after acquiring an additional 1,509,745 shares in the last quarter. Finally, Capital World Investors raised its position in Johnson & Johnson by 4.1% during the second quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock valued at $3,507,009,000 after acquiring an additional 1,050,000 shares in the last quarter. 65.90% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply